Godeau B, Mainardi J L, Roudot-Thoraval F, Hachulla E, Guillevin L, Huong Du L T, Jarrousse B, Remy P, Schaeffer A, Piette J C
Service de Médecine Interne, Hôpital Henri Mondor, Créteil, France.
Ann Rheum Dis. 1995 Dec;54(12):991-4. doi: 10.1136/ard.54.12.991.
To determine the factors associated with the occurrence of Pneumocystis carinii pneumonia (PCP) in Wegener's granulomatosis (WG).
We retrospectively compared a group of 12 patients with WG and PCP (PCP group), with 32 WG patients without PCP followed over the same period in the same centres (control group).
The mean delay of onset of PCP after the start of the immunosuppressive therapy was 127 (SD 128) days. Before treatment, the clinical and biological features of the two groups were similar, except for the mean lymphocyte count which was lower in the PCP group than in the control group (1060/mm3 v 1426/mm3; p = 0.04). During treatment, both groups were lymphopenic. There was a significant difference between the lowest absolute lymphocyte count in each group (244/mm3 in the PCP group v 738/mm3 in the control group; p = 0.001). During the first three months of treatment, the lymphocyte count was less than 600/mm3 at least once in 10 of the 12 patients in the PCP group and in 11 of the 32 patients in the control group (p < 0.01). The mean cumulative dose of cyclophosphamide was greater in the PCP group than in the control group at the end of both the second (1.55 mg/kg/day v 0.99 mg/kg/day; p = 0.05) and the third (1.67 mg/kg/day v 0.97 mg/kg/day; p = 0.03) months. However, in multivariate analysis, the only two factors independently and significantly associated with the occurrence of PCP were the pretreatment lymphocyte count (p = 0.018) and the lymphocyte count three months after the start of the immunosuppressive treatment (p = 0.014).
The severity of lymphocytopenia before and during immunosuppressive treatment is the factor best associated with PCP in WG.
确定与韦格纳肉芽肿(WG)患者发生卡氏肺孢子虫肺炎(PCP)相关的因素。
我们回顾性比较了一组12例患有WG和PCP的患者(PCP组)与同期在相同中心随访的32例无PCP的WG患者(对照组)。
免疫抑制治疗开始后PCP发病的平均延迟时间为127(标准差128)天。治疗前,两组的临床和生物学特征相似,但PCP组的平均淋巴细胞计数低于对照组(1060/mm³对1426/mm³;p = 0.04)。治疗期间,两组均出现淋巴细胞减少。每组最低绝对淋巴细胞计数之间存在显著差异(PCP组为244/mm³,对照组为738/mm³;p = 0.001)。在治疗的前三个月,PCP组12例患者中有10例、对照组32例患者中有11例淋巴细胞计数至少有一次低于600/mm³(p < 0.01)。在第二个月(1.55 mg/kg/天对0.99 mg/kg/天;p = 0.05)和第三个月(1.67 mg/kg/天对0.97 mg/kg/天;p = 0.03)末,PCP组环磷酰胺的平均累积剂量均高于对照组。然而,在多变量分析中,与PCP发生独立且显著相关的仅有的两个因素是治疗前淋巴细胞计数(p = 0.018)和免疫抑制治疗开始三个月后的淋巴细胞计数(p = 0.014)。
免疫抑制治疗前及治疗期间淋巴细胞减少的严重程度是与WG患者发生PCP最相关的因素。